← Back to catalogue
Research draft

hypertrophic cardiomyopathy

vr.tr.hypertrophic-cardiomyopathy · XCT.STA

Let an agent explain HCM in general terms, relay genetics, types, risks, treatment and family screening from cardiology sources, route collapse, fainting on exertion or chest pain to emergency care, describe the named forms and phenocopies, and distinguish HCM from athlete s heart, hypertensive heart disease, dilated cardiomyopathy and amyloidosis, without diagnosing individuals.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain HCM in general terms, relay genetics, types, risks, treatment and family screening from cardiology sources, route collapse, fainting on exertion or chest pain to emergency care, describe the named forms and phenocopies, and distinguish HCM from athlete s heart, hypertensive heart disease, dilated cardiomyopathy and amyloidosis, without diagnosing individuals.

A condition in which the heart muscle, usually of the left ventricle, becomes abnormally thick without another cause such as high blood pressure, most often due to inherited sarcomere gene variants such as in MYH7 and MYBPC3, affecting roughly 1 in 500 people, with forms including hypertrophic obstructive cardiomyopathy, apical hypertrophic cardiomyopathy and infantile forms, and conditions that mimic it, such as glycogen storage, lysosomal storage and mitochondrial diseases with hypertrophic cardiomyopathy; it can cause breathlessness, chest pain, arrhythmias and sudden cardiac death, is managed with medicines including the cardiac myosin inhibitor mavacamten, approved in the United States in 2022, septal reduction and implantable defibrillators, and relatives are offered screening. Collapse needs CPR and a defibrillator immediately.

What it is for: Not applicable; a heart muscle disease.

It can be explain in general terms; relay genetics and family screening; describe named forms; route cardiac emergencies.

Distinguishing features

Inherited

Thickened ventricle

Sudden death risk

Family screening

What it looks like

Not visible externally; seen on echocardiography or MRI as thickened heart walls.

Physical character

prevalence: about 1 in 500 people - commonly cited

common genes: MYH7 and MYBPC3 list

mavacamten FDA approval: 2022 year

wall thickness criterion: 15 mm or more in adults note - typical diagnostic threshold

How it is recognised

Genetic thickening of the heart muscle

Infantile hypertrophic cardiomyopathy, mitochondrial, glycogen storage and lysosomal disease with HCM, apical HCM, hypertrophic obstructive cardiomyopathy

Athlete s heart is adaptive; hypertensive heart disease has a pressure cause; dilated cardiomyopathy thins walls; amyloidosis infiltrates tissue

Related models

is a kind of - in registry terms

intrinsic cardiomyopathy

is treated with - for high risk

implantable cardioverter-defibrillator

includes -

hypertrophic obstructive cardiomyopathy

is contrasted with -

athletic heart syndrome

In practice

Families and kinds

obstructive HCM

non-obstructive HCM

apical HCM

infantile HCM

phenocopies such as storage and mitochondrial diseases

Standards and regulation

ESC 2023 cardiomyopathy guidelines

AHA/ACC 2024 HCM guideline

Sports cardiology screening policies

Failure modes and hazards

Missing warning signs of sudden cardiac death

Diagnosing individuals remotely

Overstating sports restrictions without current guidance

Also called

cardiomyopathy, infantile hypertrophicmitochondrial disease with hypertrophic cardiomyopathyapical hypertrophic cardiomyopathyhypertrophic obstructive cardiomyopathyglycogen storage disease with hypertrophic cardiomyopathylysosomal disease with hypertrophic cardiomyopathyfatty acid oxidation and ketogenesis disorder with hypertrophic cardiomyopathysyndrome associated with hypertrophic cardiomyopathynon-familial hypertrophic cardiomyopathyfamilial hypertrophic cardiomyopathy

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Understand What HCM is.

Attribution.

Definition

Definition.

Definition

Definition.

  1. What is hypertrophic cardiomyopathy, and how does it differ from athlete s heart, hypertensive heart disease, dilated cardiomyopathy and amyloidosis? definition
  2. Has someone collapsed, fainted during exercise or has chest pain, in which case call emergency services, start CPR and use a defibrillator? boundary

Forms

Named forms.

Forms

Forms.

  1. What are obstructive, apical and infantile HCM and storage and mitochondrial diseases with HCM? definition
  2. Which entry fits the specific form? action
Medical Genetics and diagnosis.

Attribution.

Genetics

Genetics.

Genetics

Genetics.

  1. How is HCM inherited, and how are relatives screened? provenance
  2. Which references are standard? provenance

Diagnosis

Diagnosis.

Diagnosis

Diagnosis.

  1. How is HCM diagnosed with ECG, echocardiography and MRI? provenance
  2. Which sources are cited? provenance
Treatment Treatment.

Regulation.

Therapy

Medicines and procedures.

Therapy

Therapy.

  1. How are beta blockers, myosin inhibitors and septal reduction used, in general terms? provenance
  2. Which entry fits mavacamten? action

Sudden death

Sudden death prevention.

Sudden death

Sudden death.

  1. How do guidelines assess sudden death risk and ICD use? provenance
  2. Which entry fits sudden cardiac death? action
Context Sport and support.

Context.

Sport

Sport participation.

Sport

Sport.

  1. How have sports guidelines for people with HCM changed, with positions attributed? provenance
  2. Is the presentation current and attributed? boundary

Support

Support.

Support

Support.

  1. Which organisations support families affected by cardiomyopathy? provenance
  2. Which entry fits Cardiomyopathy UK? action

What the second pass must settle

  • Should phenocopies be separate entries?
  • How should cardiology guidelines be linked?
  • How should new therapies be kept current?